doi: 10.3389/fimmu.2026.1793440 Received 22 January 2026 Revised 25 February 2026 Accepted 06 March 2026 Published 23 March 2026 Volume 17 - 2026 Edited by Baocun Zhang, Aarhus University, Denmark Reviewed by Yibo Ma, Second Affiliated Hospital of Dalian Medical University, China Daniela Poenaru, Carol Davila University of Medicine and Pharmacy, Romania Updates Copyright 2026 Chen, Gao, Luo, Wang, Niken, Xu, Ding and Guo
Costell M, Mguez MP, OConnor JE, Grisola S
Aging pathobiology and therapeutics , 2 (1), 58
doi: 10.1016/J.REDOX.2015.07.008 39 ChainyGBNSahooDK
It's calibration
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) still in phase 3 trials, whilst tesamorelin is a synthetic GHRH analogue licensed only for HIV-associated lipodystrophy in the US